Developer docs
API playgroundTry for free, no card

Search company profiles

Lilly Australia

Full company profile

uuid02icr8g

Namestring
Lilly Australia
Legal namestring
Lilly Australia
Websiteurl
lilly.com.au
Company typeenum
Private
Founded yearint
1876
Descriptiontext

Lilly Australia is the Australian operating subsidiary of Eli Lilly and Company (NYSE: LLY), a US-headquartered multinational pharmaceutical company founded in 1876. The Australian entity operates from Sydney with 251-500 employees and markets patented prescription medicines across eight therapeutic areas: arthritis, cancer, dermatology, diabetes, migraine, obesity, sleep apnoea, and Alzheimer's disease. Its flagship product in Australia is Mounjaro (tirzepatide) for type 2 diabetes, alongside a broader portfolio of genetic medicine research aimed at developing therapies tailored to individual biology.

The company's revenue model centers on prescription medication sales distributed through Australian pharmacies, healthcare providers, and the LillyDirect direct-to-consumer platform, which connects patients with independent doctors. Pricing is mediated through the Pharmaceutical Benefits Scheme (PBS) for subsidized access or private prescription channels. In 2026, Lilly Australia withdrew Mounjaro from the PBS listing process due to a pricing dispute with the federal government, an event that affected approximately 450,000 Australians with type 2 diabetes. The subsidiary is supported by the parent company's 150-year heritage, 100+ patented medications, and 2 Nobel Prizes for medicine, and engages in cultural partnerships such as Vivid Sydney 2026 for brand awareness.

Short descriptiontext

Lilly Australia is the Australian subsidiary of Eli Lilly and Company, developing and supplying patented prescription medicines across diabetes, obesity, oncology, neurology, and immunology, distributed through pharmacies, healthcare providers, and the LillyDirect platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
prescription pharmaceuticals, diabetes medications, oncology treatments, neurology therapeutics, clinical trial research
Industry2 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Prescription Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOthers
Description

Revenue generated from patented medications sold to patients and healthcare providers through pharmacies and medical channels

lilly.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Quote-based pricing through healthcare system
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing negotiated through Pharmaceutical Benefits Scheme (PBS) or private prescription. Approximately 450,000 Australians with type 2 diabetes affected by Mounjaro withdrawal from PBS listing process.

abc.net.au
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LillyDirect
Description

A direct-to-consumer healthcare service connecting patients with independent doctors who understand their conditions.

lilly.com
Core offering1 text field

Lilly Australia develops, registers, and supplies patented prescription medicines across multiple therapeutic areas including diabetes, obesity, arthritis, cancer, dermatology, migraine, sleep apnoea, and Alzheimer's disease. The company also operates the LillyDirect platform connecting patients with independent doctors, conducts patient recruitment for clinical trials, and runs affordability/access programs to support treatment uptake in Australia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lilly Australia is a pharmaceutical company that develops and manufactures medicines. The company operates across multiple therapeutic areas including Arthritis, Cancer, Dermatology, Diabetes, Migraine, Obesity, Sleep apnoea, and Alzheimer's disease. Their product portfolio centers on patented medications, with key offerings including Mounjaro (tirzepatide) for diabetes treatment. The company provides patient-facing services such as finding care through independent doctors, joining clinical trials, and accessing medicines through affordability programs. They also conduct research in genetic medicines.

Product and service3 records
1Mounjaro (tirzepatide)
CategoryPrescription Pharmaceuticals - Diabetes
Description

A patented prescription medication (tirzepatide) for the treatment of type 2 diabetes in adult patients. Sold in Australia through physician prescriptions, the Pharmaceutical Benefits Scheme (PBS), and private prescription channels.

2LillyDirect Platform
3Clinical Trial Participation Program
CategoryClinical Research Services
Description

A program offering Australian patients the opportunity to enroll in clinical trials for Lilly's investigational medicines across therapeutic areas such as arthritis, cancer, dermatology, diabetes, migraine, obesity, sleep apnoea, and Alzheimer's disease. Supports R&D pipeline progression.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-01-01
Description

Lilly Australia was a key partner for Vivid Sydney 2026, the world's largest multidisciplinary arts festival. The partnership was part of brand awareness and community engagement initiatives in Australia.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1AbbVie Australia
TypeDirect peer
Description

Australian subsidiary of AbbVie, with a heavy focus on immunology (Humira/Skyrizi/Rinvoq) and oncology. Comparable to Lilly Australia in specialty-pharma distribution, immunology presence, and PBS-listed product portfolio.

2Sanofi Australia
TypeDirect peer
Description

Australian subsidiary of Sanofi, focused on specialty care, immunology (Dupixent), diabetes, and rare disease. Comparable to Lilly Australia in operating model and therapeutic area overlap, particularly in immunology and diabetes.

TypeDirect peer
Description

Australian subsidiary of Pfizer, a large multinational pharmaceutical company. Comparable to Lilly Australia in operating model — multi-therapeutic-area branded pharma distribution, PBS participation, and direct subsidiary structure of a US parent.

4Roche Australia
TypeDirect peer
Description

Australian subsidiary of Roche, with a strong oncology and specialty-care portfolio. Comparable to Lilly Australia in the Australian branded-pharma distribution model, hospital/specialty channel access, and participation in PBS listings across multiple therapeutic areas.

5Novo Nordisk Australia
TypeDirect peer
Description

Australian subsidiary of Novo Nordisk, the direct global competitor in the GLP-1/incretin class with Ozempic and Wegovy. Comparable to Lilly Australia as a major-country pharmaceutical subsidiary focused heavily on diabetes and obesity, competing head-to-head on Mounjaro.

6Merck Sharp & Dohme (MSD) Australia
TypeDirect peer
Description

Australian subsidiary of Merck & Co., with a major oncology (Keytruda) and vaccines portfolio. Comparable to Lilly Australia as a large multinational pharma subsidiary distributing PBS-listed branded medicines across multiple therapeutic areas.

TypeDirect peer
Description

Australian subsidiary of AstraZeneca with a broad oncology, cardiovascular, and respiratory portfolio. Comparable to Lilly Australia as a multinational pharma subsidiary operating across multiple therapeutic areas with PBS-listed products in Australia.

8GSK Australia
TypeDirect peer
Description

Australian subsidiary of GSK, operating across specialty medicines, vaccines, and HIV. Comparable to Lilly Australia in the multi-therapeutic branded pharma distribution model and PBS participation.

TypeDirect peer
Description

Australian pharmaceutical arm of J&J, with a strong oncology, immunology, and neuroscience portfolio. Comparable to Lilly Australia in the multi-therapeutic branded pharma model, hospital/specialty channel presence, and PBS participation.

TypeDirect peer
Description

Australian subsidiary of Bayer, with a pharmaceutical portfolio spanning women's health, cardiology, and specialty care. Comparable to Lilly Australia as a multinational pharma subsidiary with PBS-listed products and multi-therapeutic-area coverage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lilly Australia

Prescription Pharmaceuticalslilly.com.au

Lilly Australia is the Australian subsidiary of Eli Lilly and Company, developing and supplying patented prescription medicines across diabetes, obesity, oncology, neurology, and immunology, distributed through pharmacies, healthcare providers, and the LillyDirect platform.

What Lilly Australia does

Lilly Australia is the Australian operating subsidiary of Eli Lilly and Company (NYSE: LLY), a US-headquartered multinational pharmaceutical company founded in 1876. The Australian entity operates from Sydney with 251-500 employees and markets patented prescription medicines across eight therapeutic areas: arthritis, cancer, dermatology, diabetes, migraine, obesity, sleep apnoea, and Alzheimer's disease. Its flagship product in Australia is Mounjaro (tirzepatide) for type 2 diabetes, alongside a broader portfolio of genetic medicine research aimed at developing therapies tailored to individual biology.

The company's revenue model centers on prescription medication sales distributed through Australian pharmacies, healthcare providers, and the LillyDirect direct-to-consumer platform, which connects patients with independent doctors. Pricing is mediated through the Pharmaceutical Benefits Scheme (PBS) for subsidized access or private prescription channels. In 2026, Lilly Australia withdrew Mounjaro from the PBS listing process due to a pricing dispute with the federal government, an event that affected approximately 450,000 Australians with type 2 diabetes. The subsidiary is supported by the parent company's 150-year heritage, 100+ patented medications, and 2 Nobel Prizes for medicine, and engages in cultural partnerships such as Vivid Sydney 2026 for brand awareness.

Lilly Australia firmographics

Firmographics
Name
Lilly Australia
Legal name
Lilly Australia
Website
https://lilly.com.au
Company type
Private
Founded year
1876
Operating status
Operating
Headcount range
251–500 employees
Short description
Lilly Australia is the Australian subsidiary of Eli Lilly and Company, developing and supplying patented prescription medicines across diabetes, obesity, oncology, neurology, and immunology, distributed through pharmacies, healthcare providers, and the LillyDirect platform.
Ownership category
akta.pro rank

Lilly Australia industry classification

Industry
Product category
Prescription Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Prescription pharmaceuticals
  • Diabetes medications
  • Oncology treatments
  • Neurology therapeutics
  • Clinical trial research

Where Lilly Australia is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Markets served

Lilly Australia business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from patented medications sold to patients and healthcare providers through pharmacies and medical channels

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing through healthcare system

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Lilly Australia product offering

Product offering

Core offering

Lilly Australia develops, registers, and supplies patented prescription medicines across multiple therapeutic areas including diabetes, obesity, arthritis, cancer, dermatology, migraine, sleep apnoea, and Alzheimer's disease. The company also operates the LillyDirect platform connecting patients with independent doctors, conducts patient recruitment for clinical trials, and runs affordability/access programs to support treatment uptake in Australia.

Product overview

Lilly Australia is a pharmaceutical company that develops and manufactures medicines. The company operates across multiple therapeutic areas including Arthritis, Cancer, Dermatology, Diabetes, Migraine, Obesity, Sleep apnoea, and Alzheimer's disease. Their product portfolio centers on patented medications, with key offerings including Mounjaro (tirzepatide) for diabetes treatment. The company provides patient-facing services such as finding care through independent doctors, joining clinical trials, and accessing medicines through affordability programs. They also conduct research in genetic medicines.

Differentiator

Problem solved

Functional benefit

Brands

  • LillyDirect: A direct-to-consumer healthcare service connecting patients with independent doctors who understand their conditions.

Products and services

  • Mounjaro (tirzepatide) A patented prescription medication (tirzepatide) for the treatment of type 2 diabetes in adult patients. Sold in Australia through physician prescriptions, the Pharmaceutical Benefits Scheme (PBS), and private prescription channels.
  • LillyDirect Platform
  • Clinical Trial Participation Program A program offering Australian patients the opportunity to enroll in clinical trials for Lilly's investigational medicines across therapeutic areas such as arthritis, cancer, dermatology, diabetes, migraine, obesity, sleep apnoea, and Alzheimer's disease. Supports R&D pipeline progression.

Companies that use Lilly Australia

Customer profile

Segments8 records

Ideal customer profiles3 records

Lilly Australia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Lilly Australia partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Vivid SydneyminorGTM or Marketing Partner · 1 January 2026Lilly Australia was a key partner for Vivid Sydney 2026, the world's largest multidisciplinary arts festival. The partnership was part of brand awareness and community engagement initiatives in Australia.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Lilly Australia competitors and assessment

Company assessment

Direct peers

  • AbbVie Australia: Australian subsidiary of AbbVie, with a heavy focus on immunology (Humira/Skyrizi/Rinvoq) and oncology. Comparable to Lilly Australia in specialty-pharma distribution, immunology presence, and PBS-listed product portfolio.
  • Sanofi Australia: Australian subsidiary of Sanofi, focused on specialty care, immunology (Dupixent), diabetes, and rare disease. Comparable to Lilly Australia in operating model and therapeutic area overlap, particularly in immunology and diabetes.
  • Pfizer Australia: Australian subsidiary of Pfizer, a large multinational pharmaceutical company. Comparable to Lilly Australia in operating model — multi-therapeutic-area branded pharma distribution, PBS participation, and direct subsidiary structure of a US parent.
  • Roche Australia: Australian subsidiary of Roche, with a strong oncology and specialty-care portfolio. Comparable to Lilly Australia in the Australian branded-pharma distribution model, hospital/specialty channel access, and participation in PBS listings across multiple therapeutic areas.
  • Novo Nordisk Australia: Australian subsidiary of Novo Nordisk, the direct global competitor in the GLP-1/incretin class with Ozempic and Wegovy. Comparable to Lilly Australia as a major-country pharmaceutical subsidiary focused heavily on diabetes and obesity, competing head-to-head on Mounjaro.
  • Merck Sharp & Dohme (MSD) Australia: Australian subsidiary of Merck & Co., with a major oncology (Keytruda) and vaccines portfolio. Comparable to Lilly Australia as a large multinational pharma subsidiary distributing PBS-listed branded medicines across multiple therapeutic areas.
  • AstraZeneca Australia: Australian subsidiary of AstraZeneca with a broad oncology, cardiovascular, and respiratory portfolio. Comparable to Lilly Australia as a multinational pharma subsidiary operating across multiple therapeutic areas with PBS-listed products in Australia.
  • GSK Australia: Australian subsidiary of GSK, operating across specialty medicines, vaccines, and HIV. Comparable to Lilly Australia in the multi-therapeutic branded pharma distribution model and PBS participation.
  • Johnson & Johnson Innovative Medicine Australia (Janssen): Australian pharmaceutical arm of J&J, with a strong oncology, immunology, and neuroscience portfolio. Comparable to Lilly Australia in the multi-therapeutic branded pharma model, hospital/specialty channel presence, and PBS participation.
  • Bayer Australia: Australian subsidiary of Bayer, with a pharmaceutical portfolio spanning women's health, cardiology, and specialty care. Comparable to Lilly Australia as a multinational pharma subsidiary with PBS-listed products and multi-therapeutic-area coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Lilly Australia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lilly Australia leadership team

Management profile

Number of profiles

Lilly Australia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lilly Australia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lilly Australia

What does Lilly Australia do?

Lilly Australia develops, registers, and supplies patented prescription medicines across multiple therapeutic areas including diabetes, obesity, arthritis, cancer, dermatology, migraine, sleep apnoea, and Alzheimer's disease. The company also operates the LillyDirect platform connecting patients with independent doctors, conducts patient recruitment for clinical trials, and runs affordability/access programs to support treatment uptake in Australia.

Is Lilly Australia a public or private company?

Lilly Australia is a private company. It is classified as corporate owned and is currently operating.

When was Lilly Australia founded?

Lilly Australia was founded in 1876. It employs 251 to 500 people.

Where is Lilly Australia based?

Lilly Australia is headquartered in Sydney, Australia, in the Oceania region.

How does Lilly Australia make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Lilly Australia's main competitors?

Direct peers on record are AbbVie Australia, Sanofi Australia, Pfizer Australia, Roche Australia, Novo Nordisk Australia, Merck Sharp & Dohme (MSD) Australia, AstraZeneca Australia, GSK Australia, Johnson & Johnson Innovative Medicine Australia (Janssen) and Bayer Australia.

Does Lilly Australia have an API?

No public API is recorded for Lilly Australia.

What industry is Lilly Australia in?

Lilly Australia's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsCross-Sector Alliance to Tackle Alzheimer's in AustraliaA three-way Memorandum of Understanding was signed in Sydney by Neuroscience Research Australia (NeuRA), Roche Diagnostics Australia, and Lilly Australia to create a blueprint for tackling Australia's dementia crisis, which affects roughly 450,000 Australians with numbers expected to reach one million by 2065. The collaboration will pilot a new care model integrating blood-based biomarkers, imaging, and treatments into streamlined referral pathways, initially focusing on New South Wales at the Randwick Health & Innovation Precinct. The partnership aims to develop clinical guidance, build healthcare workforce capability, and establish a replicable model for early Alzheimer's diagnosis and equitable access to treatments across Australia.PR NewswireÀ l'heure où les lumières s'éteignent, Vivid Sydney 2026 quitte une ville rayonnanteVivid Sydney 2026 concluded its 23-night run, marking the end of another edition of the world's largest multidisciplinary arts festival held in Sydney, Australia. The festival featured over 200 events across five interconnected zones, with more than 80% free to the public, and showcased 41 international artists making their Australian debut alongside prominent figures such as Saint Levant, Chloé Zhao, and Sean Baker. Key partners for the 2026 edition included Kia, Samsung Electronics Australia, IREN, Lilly Australia, Uber, and Foodbank NSW & ACT.PR NewswireAs the Lights Fade, Vivid Sydney 2026 Leaves the City GlowingVivid Sydney 2026 closed after 23 nights, having curated over 200 events across five zones, with more than 80% free to attend. The festival featured 41 international acts, including Academy Award winners Chloé Zhao and Sean Baker, and highlighted aerial performances and expanded Fire Kitchen. Festival director Brett Sheehy said the event exceeded expectations in sell-out shows and visitor engagement.PR Newswire APACAs the Lights Fade, Vivid Sydney 2026 Leaves the City GlowingVivid Sydney 2026 closed after 23 nights, having curated over 200 events across five zones, with more than 80% free to attend. The festival featured 41 international acts, including Academy Award winners Chloé Zhao and Sean Baker, and highlighted aerial performances and expanded Fire Kitchen. Partners Kia, Samsung, and Uber returned, with Foodbank NSW & ACT as charity partner.NewswireAs the Lights Fade, Vivid Sydney 2026 Leaves the City GlowingVivid Sydney 2026 closed after 23 nights, having curated over 200 events across five zones, with more than 80% free to attend. The festival featured 41 international acts, including Academy Award-winning director Chloé Zhao, and highlighted aerial performances and expanded Fire Kitchen. Festival director Brett Sheehy said it exceeded expectations in sell-out shows and visitor engagement.ABCBroken PBS system behind failure to list Mounjaro for type 2 diabetics, according to Medicines AustraliaEli Lilly has withdrawn its diabetes drug Mounjaro (tirzepatide) from Australia's Pharmaceutical Benefits Scheme listing process after a pricing dispute with the federal government, leaving approximately 450,000 Australians with type 2 diabetes unable to access the medication at subsidized costs. Medicines Australia CEO Liz de Somer described the Australian PBS system as "broken," citing excessive complexity, lengthy approval timelines averaging 22 months, and a process that undervalues pharmaceutical innovation. A Health Technology Assessment review was delivered to the government in 2024 with recommendations to streamline the system, but industry advocates say urgent action is needed to prevent further access failures.MedianetUNIQUE CROSS-SECTOR COLLABORATION TO DRIVE BEST PRACTICE IN TACKLING ALZHEIMER’S DISEASE IN AUSTRALIA – News HubA three-way Memorandum of Understanding was signed in Sydney by Neuroscience Research Australia (NeuRA), Roche Diagnostics Australia, and Lilly Australia to create a blueprint for tackling Australia's dementia crisis. The collaboration will pilot a new care model integrating blood-based biomarkers, imaging, and treatments into streamlined referral pathways, initially focused on New South Wales with the aim of national replication. Dementia is the leading cause of death in Australia, with approximately 450,000 Australians currently living with the condition and numbers expected to reach one million by 2065.